220 résultats
Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Auteurs / Authors
V. Gounant, L. Greillier, C. Mascaux, F. Pinquie, D. Carmier, L. Moreau, B. Roch, D. Debieuvre, X. Dhalluin, E. Giroux-leprieur, E. Berton, A. Rabeau, J. Raimbourg, A. Dixmier, C. Naltet, A. Khalil, L. Ezzeddine, A. Langlais, F. Morin, M. Duruisseaux
Journal / Conference
ESMO
Année / Year
2024
PMID / session
Etude IFCT
Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)
Auteurs / Authors
D. Planchard, J. Mazieres, C. Mascaux, F. Guisier, P. Tomasini, M. Wislez, D. Moro-Sibilot, S. Cousin, A.B. Cortot, S. Couraud, V. Fallet, C. Guguen, A. Lagrange, A-C. Madroszyk Flandin, J. Otto, M. Pérol, B. Roch, E. Amour, F. Morin, C. Ricordel
Journal / Conference
ESMO
Année / Year
2024
PMID / session
Etude IFCT
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Auteurs / Authors
G. Goss, G.E. Darling, V. Westeel, K. Nakagawa, B. Massuti Sureda, F. Perrone, S-A. McLachlan, J.H. Kang, Y-L. Wu, A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, S. Sugawara, E. Nadal, A. Catino, M.R. Stockler, K. Ding, C. O’Callaghan
Journal / Conference
ESMO
Année / Year
2024
PMID / session
Etude IFCT
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
Auteurs / Authors
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB.
Journal / Conference
Lung Cancer
Année / Year
2024
PMID / session
Etude IFCT
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Auteurs / Authors
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P
Journal / Conference
Lancet Oncology
Année / Year
2024
PMID / session
Etude IFCT
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
Auteurs / Authors
Moro-Sibilot D, Falchero L, Ardin C, Zouak A, Molinier O, Romand P, Leleu O, Amrane K, Berndt C, Langlais A, Morin F, Westeel V
Journal / Conference
Respiratory Medicine and Research
Année / Year
2024
PMID / session
Etude IFCT
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
Auteurs / Authors
Diane Damotte; Yoan Velut; Barbara Burroni; Gary Birsen; Julien Lavergne; Audrey Mansuet-Lupo; Isabelle Cremer; Julien Mazieres; Jacques Cadranel; Gerard Zalcman; Radj Gervais; Gaelle Jeannin; Olivier Molinier; Thomas Egenod; Olivier Carre; Celia Berndt; Alexandra Langlais; Franck Morin; Virginie Westeel; Marie Wislez
Journal / Conference
ASCO
Année / Year
2024
PMID / session
Etude IFCT
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
Auteurs / Authors
Baptiste Oudart J, Garinet S, Leger C, Barlesi F, Mazières J, Jeannin G, Audigier-Valette C, Morot-Sibilot D, Langlais A, Amour E, Mathiot N, Birsen G, Blons H, Wislez M
Journal / Conference
Lung Cancer
Année / Year
2024
PMID / session
Etude IFCT
Osimertinib chez les patients atteint d’un cancer bronchique non à petites cellules (CBNPC) muté EGFR présentant des métastases cérébrales ou leptoméningées : résultats de l’étude IFCT-1804 ORBITAL
Auteurs / Authors
D. Planchard, A.C. Toffart, A. Madroszyk, M. Wislez, S. Martinez, I. Monnet, S. Hiret, V. Gounant, A.C. Métivier, C. Domblides, E. Giroux-Leprieur, E. Huchot, P. Tomasini, C. Mascaux, D. Carmier, A. Langlais, F. Morin, A. Westeel, A. Cortot
Journal / Conference
CPLF
Année / Year
2024
PMID / session
Etude IFCT
Traitement des cancers bronchiques à petites cellules (CBPC) : Intérêt des études en vie réelle. A propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin
Auteurs / Authors
L. Falchero, C. Mascaux, J.B. Auliac, J. Raimbourg, A. Baranzelli, P. Fournel, B. Leterre, L. Rajpar, J. Madelaine, A. Ampere, M. Ravoire, C. Ricordel, K. Amrane, P. Foucher, W. Al Sheikh, S. Schneider, F. Morin, P. Missy, V. Westeel, N. Girard
Journal / Conference
CPLF
Année / Year
2024
PMID / session
Etude IFCT
Efficacité et tolérance du sotarasib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation KRAS G12C : résultats de l’étude en vie réelle IFCT-2102 Lung KG12Ci
Auteurs / Authors
M. Wislez, C Mascaux, J Cadranel, Q. D. Thomas, C Ricordel, A Swalduz, E Pichon, R Veillon, V Gounant, G Rousseau-Bussac, A Madroszyk, C Daniel, M Ravoire, A-C Metivier, P Fournel, P Missy, F Morin, F Guisier , V Westeel
Journal / Conference
CPLF
Année / Year
2024
PMID / session
Etude IFCT
Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227, IFCT-1901)
Auteurs / Authors
L. Greillier, M. Locatelli Sanchez, Q. Chu, F. Perrone, G. Zalcman, X. Quantin, J. Mazieres, I. Monnet, J. Madelaine, H. Almotlak, S. Hiret, D. Planchard, O. Molinier, E. Giroux Leprieur, C. Ricordel, C. Clement-Duchene, S. Cousin, C. Mascaux, C. Audigier-Valette, C. Berndt, L. Seymour, F. Morin, V. Westeel, A. Scherpereel
Journal / Conference
CPLF
Année / Year
2024
PMID / session
Etude IFCT
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Auteurs / Authors
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L.
Journal / Conference
The Lancet
Année / Year
2023
PMID / session
Etude IFCT
Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
Auteurs / Authors
G. Eberst, J. Henriques, M. Monchatre, E. Giroux-Leprieur, E. Kelkel, A. Bizieux Thaminy, P. Ravier, P. Thomas, S. Bayle, C. Audigier Valette, H. Berard, F. Desliers, A. Lagrange, P. Bonnefoy, A. Langlais, D. Vernerey, A. Anota, F. Morin, V. Westeel
Journal / Conference
ESMO
Année / Year
2023
PMID / session
Etude IFCT
Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7-IFCT-1402): a prospective multicentre, open-label, randomised, controlled trial
Auteurs / Authors
P. Vera, F. Le Tinier, P. Chaumet-Riffaud, E. Martin, N. Pourel, P. Boisselier, N. Salem, C. Le Pechoux, E. Giroux-Leprieur, S. Guillerm, C. Audigier Valette, D. Lerouge, C. Massabeau, P. Moisson, A. Larrouy, S. Hapdey, A. Langlais, E. Amour, G. Zalcman, P. Giraud, S. Thureau
Journal / Conference
ESMO
Année / Year
2023
PMID / session
Etude IFCT
Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Auteurs / Authors
M. Wislez, C Mascaux, J Cadranel, Q. D. Thomas, C Ricordel, A Swalduz, E Pichon, R Veillon, V Gounant, G Rousseau-Bussac, A Madroszyk, C Daniel, M Ravoire, A-C Metivier, P Fournel, P Missy, F Morin, F Guisier , V Westeel
Journal / Conference
ESMO
Année / Year
2023
PMID / session
Etude IFCT
Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Auteurs / Authors
D. Planchard, A.C. Toffart, A.C. Madroszyk, M. Wislez, S. Martinez, I. Monnet, S. Hiret, V. Gounant, A.C. Métivier, C. Domblides , E. Giroux-Leprieur, E. Huchot, P. Tomasini, C. Mascaux, D. Carmier, A. Langlais, F. Morin, V. Westeel, A. Cortot
Journal / Conference
ESMO
Année / Year
2023
PMID / session
Etude IFCT
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study
Auteurs / Authors
Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, Merle P, Lamy R, Madroszyk A, Otto J, Tomasini P, Assoun S, Canellas A, Gervais R, Hureaux J, Le Treut J, Leleu O, Naltet C, Tiercin M, Van Hulst S, Missy P, Morin F, Westeel V, Girard N
Journal / Conference
Lung Cancer
Année / Year
2023
PMID / session
Etude IFCT
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial
Auteurs / Authors
Levallet G, Dubois F, Elie N, Creveuil C, Brosseau S, Danel C, Scherpereel A, Lantuejoul S, Mazières J, Greillier L, Audigier-Valette C, Bergot E, Moro-Sibilot D, Molinier O, Léna H, Monnet I, Morin F, Gounant V, Zalcman G
Journal / Conference
Lung Cancer
Année / Year
2023
PMID / session
Etude IFCT
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).
Auteurs / Authors
Nicolas Girard, Florian Guisier, Aurélie Swalduz, Sylvie Van Hulst, Eric Pichon, Pernelle Lavaud, Laurent Greillier, Angelica Tiotiu, Anne Madroszyk, Olivier Bylicki, Anthony Canellas, Laure Belmont, Maeva Zysman, Pierre-Alexandre Hauss, Benoit Godbert, Clarisse Audigier-Valette, Cléa Lebreton, Franck Morin, Virginie Westeel
Journal / Conference
ASCO
Année / Year
2023
PMID / session
Etude IFCT
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Auteurs / Authors
Lionel Falchero, Florian Guisier, Marie Darrason, Arnaud Boyer, Charles Dayen, Sophie Cousin, Patrick Merle, Regine Lamy, Anne Madroszyk, Josiane Otto, Pascale Tomasini, Pascale Missy, Franck Morin, Virginie Westeel, Nicolas Girard
Journal / Conference
ASCO
Année / Year
2023
PMID / session
Etude IFCT
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial
Auteurs / Authors
Gerard Zalcman, Anne Madroszyk, Charles Dayen, Olivier Molinier, Thomas Egenod, Didier Debieuvre, Sophie Beaucaire-Danel, Adrien Dixmier, Eric Pichon, Sigolène Galland-Girodet, Etienne Giroux Leprieur, Nicolas Cloarec, Jacques Cadranel, Josiane Otto, Nicolas Poté, Alexandra Langlais, Franck Morin, Martine Antoine, Virginie Westeel, Anne-Claire Toffart
Journal / Conference
ASCO
Année / Year
2023
PMID / session
Etude IFCT
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
Auteurs / Authors
Quincy S. Chu, Maria Carmela Piccirillo, Laurent Greillier, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Penelope Ann Bradbury, Alessandro Morabito, Fabiana Letizia Cecere, Sara Delfanti, Arnaud Scherpereel, Myriam Locatelli-Sanchez, Gerard Zalcman, David E Dawe, Joana Sederias, Scott A. Laurie, Christopher W. Lee, Wei Tu, Lesley Seymour
Journal / Conference
ASCO
Année / Year
2023
PMID / session
Etude IFCT
Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.
Auteurs / Authors
Filippo Gustavo Dall'Olio, Damien Vasseur, Maryam Karimi, Stefan Michiels, Ludovic Lacroix, Pascale Tomasini, Judith Raimbourg, Noemie pata-Merci, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Ivan Bieche, Julien Mazieres, Denis Lucien MORO SIBILOT, Marta Jimenez, Jean-Charles Soria, Virginie Westeel, Fabrice Barlesi, Benjamin Besse
Journal / Conference
ASCO
Année / Year
2023
PMID / session
Etude IFCT
Capmatinib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation MET exon 14 : résultats de l’étude en vraie vie IFCT-2104 CapmATU
Auteurs / Authors
Ferreira M, Greillier L, Swalduz A, Toffart A.C, Raimbourg J, Gounant V, Couraud S, Chabot (de) G, Friard S, Hureaux J, Odier L, Wislez M, Missy P, Morin F, Westeel V, Cortot A.B.
Journal / Conference
CPLF
Année / Year
2023
PMID / session
Etude IFCT
Etude de phase II-III randomisée (IFCT-1701 DICIPLE), comparant une continuation du doublet d’immunothérapie Nivolumab-Ipilimumab jusqu’à progression à une observation chez des patients avec un Cancer Bronchique Non à Petites Cellules (CBNPC) métastatique
Auteurs / Authors
Toffart A-C, Madroszyk A, Dayen C, Molinier O, Egenod T, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Langlais A, Morin F, Antoine M, Westeel V, Zalcman G.
Journal / Conference
CPLF
Année / Year
2023
PMID / session
Etude IFCT
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome
Auteurs / Authors
Mogenet A, Barlesi F, Besse B, Michiels S, Karimi M, Tran-Dien A, Girard N, Mazieres J, Audigier-Valette C, Locatelli-Sanchez M, Kamal M, Gestraud P, Hamza A, Jacquet A, Jimenez M, Yara S, Greillier L, Bertucci F, Planchard D, Soria JC, Bieche I, Tomasini P.
Journal / Conference
Lung Cancer
Année / Year
2022
PMID / session
35609409
Etude IFCT
Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Auteurs / Authors
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy F, Souquet PJ, Cloarec N, Giroux-Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, Besse B.
Journal / Conference
Clinical cancer research
Année / Year
2022
PMID / session
35802649
Etude IFCT
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
Auteurs / Authors
Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, Caliandro R, Dubos-Arvis C, Jeannin G, Molinier O, Massiani MA, Langlais A, Morin F, Le Pimpec Barthes F, Brouchet L, Assouad J, Milleron B, Damotte D, Antoine M, Westeel V
Journal / Conference
The Journal for Immunotherapy of Cancer
Année / Year
2022
PMID / session
Etude IFCT
Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial
Auteurs / Authors
Zalcman G.
Journal / Conference
ESMO
Année / Year
2022
PMID / session
Etude IFCT
Capmatinib for METex14 non-small cell lung cancer patients: results of the real-world study IFCT-2104 CapmATU
Auteurs / Authors
Ferreira M.
Journal / Conference
ESMO
Année / Year
2022
PMID / session
Etude IFCT
Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network
Auteurs / Authors
Benitez JC
Journal / Conference
ESMO
Année / Year
2022
PMID / session
Etude IFCT
Outcome of Patients With Resected Early-Stage Non-Small Cell Lung Cancer and EGFR mutations: Results from the IFCT Biomarkers France Study
Auteurs / Authors
Pierre Mordant, Solenn Brosseau, Bernard Milleron, Nicola Santelmo, Séverine Fraboulet-Moreau, Benjamin Besse, Alexandra Langlais, Dominique Gossot, Pascal-Alexandre Thomas, Jean-Louis Pujol, Charles Ricordel, Jeannick Madelaine, Régine Lamy, Clarisse Audigier-Valette, Pascale Missy, Hélène Blons, Fabrice Barlesi, Virginie Westeel, for the French Cooperative Thoracic Intergroup (IFCT),
Journal / Conference
Clinical Lung cancer
Année / Year
2022
Etude IFCT
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
Auteurs / Authors
Westeel V, Foucher P, Scherpereel A, Domas J, Girard P, Trédaniel J, Wislez M, Dumont P, Quoix E, Raffy O, Braun D, Derollez M, Goupil F, Hermann J, Devin E, Barbieux H, Pichon E, Debieuvre D, Ozenne G, Muir JF, Dehette S, Virally J, Grivaux M, Lebargy F, Souquet PJ, Freijat FA, Girard N, Courau E, Azarian R, Farny M, Duhamel JP, Langlais A, Morin F, Milleron B, Zalcman G, Barlesi F
Journal / Conference
The Lancet Oncology
Année / Year
2022
PMID / session
Etude IFCT
Availability of results of academic randomized trials involving cooperative groups in oncology in France: A systematic search of clinical trial registries
Auteurs / Authors
Créquit P, Vivot A, Grégory J, Milleron B
Journal / Conference
Journal of Cancer Policy
Année / Year
2022
PMID / session
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer
Auteurs / Authors
Duruisseaux M, Swalduz A, Mazieres J, Barlesi F, Amour E, Morin F, Westeel V
Journal / Conference
ASCO
Année / Year
2022
PMID / session
Etude IFCT
The Lung ART adjuvant radiotherapy phase 3 randomized trial: Impact of quality of resection in stage IIIAN2 patients
Auteurs / Authors
Thomas PA, Edwards JG, Rami-Porta R, Van Schil P, Mercier O, Le Rochais JP, Falcoz PE, Meunier JP, Gkika E, Kheira H, Riesterer O, Rosa Ghigna M, Bardet A, Le Pechoux C, On behalf of LungART investigators (IFCT 0503, UK Lung ART Group, SAKK)
Journal / Conference
ASCO
Année / Year
2022
PMID / session
Etude IFCT
Efficacy of dabrafenib-trametinib combination in BRAF V600E-mutated metastatic non–small cell lung cancer: Results of the IFCT-2004 BLaDE cohort.
Auteurs / Authors
Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Pichon E, Missy P, Morin F, Westeel V, Auliac JB, Veillon R
Journal / Conference
ASCO
Année / Year
2022
PMID / session
Etude IFCT
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer
Auteurs / Authors
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F
Journal / Conference
Cancer/Radiothérapie
Année / Year
2022
PMID / session
Etude IFCT
A Defect of Amphiregulin Release Predicted Longer Survival Independently of YAP Expression in Patients with Pleural Mesothelioma in the IFCT-0701 MAPS Phase 3 Trial
Auteurs / Authors
Maille E, Levallet J, Dubois F, Antoine M, Danel C, Creveuil C, Mazieres J, Margery J, Greillier L, Gounant V, Moro-Sibilot D, Molinier O, Léna H, Monnet I, Bergot E, Langlais A, Morin F, Sherpereel A, Zalcman G, Levallet G
Journal / Conference
International Journal of Cancer
Année / Year
2022
PMID / session
Etude IFCT
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
Auteurs / Authors
Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S.
Journal / Conference
ESMO open
Année / Year
2022
PMID / session
Etude IFCT
Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Auteurs / Authors
Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, Cortot AB, Descourt R, Doubre H, Quantin X, Duruisseaux M, Monnet I, Moro-Sibilot D, Cadranel J, Clément-Duchêne C, Cousin S, Ricordel C, Merle P, Otto J, Schneider S, Langlais A, Morin F, Westeel V, Girard N.
Journal / Conference
European Journal of Cancer
Année / Year
2022
PMID / session
Etude IFCT
La réponse pathologique est un facteur pronostique indépendant de survie globale (SG) et sans récidive (SSR) après durvalumab en néoadjuvant dans les cancers bronchiques non à petites cellules (CBNPC) résécables dans l'essai de phase 2 IFCT-1601 IONESCO
Auteurs / Authors
M. Wislez, J. Mazières, A. Lavole, G. Zalcman, O. Carre, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M.A. Massiani, A. Langlais, F. Morin, F. Le Pimpec Barthes, L. Brouchet, J. Assouad, B. Milleron, V. Westeel, M. Antoine, D. Damotte
Journal / Conference
CPLF
Année / Year
2022
PMID / session
Etude IFCT
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
Auteurs / Authors
Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B.
Journal / Conference
Journal of Clinical Oncology
Année / Year
2022
PMID / session
Etude IFCT
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial
Auteurs / Authors
Souquet PJ, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, Gervais R, Barlesi F, Pichon E, Zalcman G, Dumont P, Girard N, Poudenx M, Mazières J, Cadranel J, Debieuvre D, Dauba J, Langlais A, Morin F, Moro-Sibilot D, Westeel V, Pérol M.
Journal / Conference
Lung Cancer
Année / Year
2022
PMID / session
Etude IFCT
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
Auteurs / Authors
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N
Journal / Conference
ESMO open
Année / Year
2021
PMID / session
Etude IFCT
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial
Auteurs / Authors
C. Le Pechoux, N. Pourel, F. Barlesi, D. Lerouge, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, E. Dansin, A. Paumier, K. Peignaux, F. Thillays, G. Zalcman, J. Madelaine, E. Pichon, A. Larrouy, A. Lavole, D. Argo-Leignel, Marc Derollez, C. Faivre-Finn, M. Q Hatton, O. Riesterer, E. Bouvier-Morel, A. Dunant, J. G Edwards, P. Alexandre Thomas, O. Mercier, A. Bardet
Journal / Conference
The Lancet Oncology
Année / Year
2021
Etude IFCT
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Auteurs / Authors
S. Peters, J-L. Pujol, U. Dafni, M. Dómine, S. Popat, M. Reck, J. Andrade, A. Becker, D. Moro-Sibilot, A. Curioni-Fontecedro, O. Molinier , K. Nackaerts , A. Insa Mollá, R. Gervais, G. López Vivanco, J. Madelaine, J. Mazieres, M. Faehling, F. Griesinger, M. Majem, J L. González Larriba , M. Provencio Pulla, K. Vervita, H. Roschitzki-Voser, B. Ruepp, P. Mitchell, R A. Stahel, C. Le Pechoux, D. De Ruysscher
Journal / Conference
Annals of Oncology
Année / Year
2021
PMID / session
Etude IFCT
Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC)
Auteurs / Authors
N. Girard, J. Mazieres, J. Otto, H. Lena, C. Lepage, T. Egenod, D. Smith, J. Madelaine, L. Gérinière, F. El Hajbi, A. Ferru, C. Clément-Duchêne, A. Madroszyk, J. Desrame, F. Morin, A. Langlais, P. Michel, C. Louvet, V. Westeel, T. Walter
Journal / Conference
ESMO
Année / Year
2021
PMID / session
Etude IFCT
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected NSCLC and mediastinal N2 involvement: characterisation of PORT efficacy in Lung ART (IFCT-0503, UK NCRI, SAKK)
Auteurs / Authors
C. Le Pechoux, N. Pourel, F. Barlesi, C. Faivre-Finn, D. Lerouge, G. Zalcman, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, F. Thillays, A. Paumier, E. Dansin, K. Peignaux, J. Madelaine, E. Pichon, A. Larrouy, O. Riesterer, A. Lavole, A. Bardet
Journal / Conference
ESMO
Année / Year
2021
PMID / session
Etude IFCT
Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial
Auteurs / Authors
M. Wislez, J. Mazieres, A. Lavole, G. Zalcman, O. Carre, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M. Massiani, A. Langlais, F. Morin, F. Le Pimpec Barthes, L. Brouchet, J. Assouad, B. Milleron, V. Westeel, M. Antoine, D. Damotte
Journal / Conference
ESMO
Année / Year
2021
PMID / session
Etude IFCT
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial
Auteurs / Authors
A. Lavole, J. Mazieres, S. Schneider, S. Brosseau, L.M. Kiakouama, L. Greillier, A. Guihot, B. Abbar, M. Baron, A. Makinson, A. Langlais, F. Morin, J-P. Spano, J. Cadranel
Journal / Conference
Lung Cancer
Année / Year
2021
Etude IFCT
Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
Auteurs / Authors
J. Mazières, C. Lafitte, C. Ricordel, L. Greillier, J. Pujol, G. Zalcman, C. Domblides, J. Madelaine, J. Bennouna, C. Mascaux, D. Moro-Sibilot, F. Pinquié, A. Cortot, J. Otto, J. Cadranel, A. Langlais, F. Morin, V. Westeel, B. Besse
Journal / Conference
ASCO
Année / Year
2021
PMID / session
Etude IFCT
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial
Auteurs / Authors
D Vasseur, C Jovelet, N Cozic, J Mazieres, F Barlesi, J Bennouna, R Gervais, L Moreau, H Berard, O Molinier, D MoroSibilot, PJ Souquet, E Amour, F Morin, G Zalcman, J-C Soria, V Westeel, L Lacroix, B Besse
Journal / Conference
ASCO
Année / Year
2021
PMID / session
Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.
Auteurs / Authors
JM. Maury, JC. Benitez, ME. Boucher, E. Dansin, M. Kerjouan, L. Bigay-Game, E.Pichon, F. Thillays, PE. Falcoz, L. Svetlana, Y. Oulkhouir, F. Calcagno, L. Thiberville, C. Clément Duchêne, V. Westeel, P. Missy, P. Alexandre Thomas, T. Molina, N. Girard, B. Besse
Journal / Conference
ASCO
Année / Year
2021
PMID / session
Etude IFCT
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
Auteurs / Authors
Wislez M, Domblides C, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano JP, Ricordel C, Fraisse P, Janicot H, Audigier-Valette C, Amour E, Langlais A, Rabbe N, Makinson A, Cadranel J, Laurent-Puig P, Lavolé A, Blons H
Journal / Conference
Lung Cancer
Année / Year
2021
PMID / session
Etude IFCT
First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study
Auteurs / Authors
Cortot AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, Charpentier S, Denis MG, Cadranel J.
Journal / Conference
Clinical Cancer Research
Année / Year
2021
PMID / session
Etude IFCT
[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]
Auteurs / Authors
Tougeron D, Seitz-Polski B, Hentzien M, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S, Gorphe P, Guiu B, Hardy-Bessard AC, Hoang Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C, Maggiori L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, Aparicio T, Blay JY, Bouché O
Journal / Conference
Bulletin du cancer
Année / Year
2021
PMID / session
Surveillance After Curative-Intent Treatment for NSCLC : More to it Than Meets the Eye
Auteurs / Authors
V. Westeel
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2021
PMID / session
Etude IFCT
Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening
Auteurs / Authors
S. Couraud, G. Ferretti, B. Milleron, A. Cortot, N. Girard, V. Gounant, F. Laurent, O. Leleu, E. Quoix, M.-P. Revel, M. Wislez, V. Westeel, G. Zalcman, A. Scherpereel, A. Khalil
Journal / Conference
Diagnostic and Interventional Imaging
Année / Year
2021
PMID / session
Recommandations de l’Intergroupe francophone de cancérologie thoracique, de la Société de pneumologie de langue française et de la Société d’imagerie thoracique sur le dépistage du cancer bronchopulmonaire par tomodensitométrie à faible dose d’irradiation
Auteurs / Authors
S. Couraud, G. Ferretti, B. Milleron, A. Cortot, N. Girard, V. Gounant, F. Laurent, O. Leleu, E. Quoix, M.-P. Revel, M. Wislez, V. Westeel, G. Zalcman, A. Scherpereel, A. Khalil
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2021
PMID / session
Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study
Auteurs / Authors
Journal / Conference
WCLC
Année / Year
2021
PMID / session
Etude IFCT
Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ROS1+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), Etude LORLATU IFCT-1803
Auteurs / Authors
N. Girard, S. Galland-Girodet, M. Duruisseaux, V. Avrillon, B. Roch, J. Otto, J. Cadranel, M. Coudurier, D. Moro-Sibilot, T. Egenod, R. Lamy, J. Bennouna, G. Zalcman, C. Ricordel, J. Tillon, L. Odier, B. Besse, P. Missy, V. Westeel, S. Baldacci
Journal / Conference
CPLF
Année / Year
2021
PMID / session
Etude IFCT
Première analyse de l’essai Lung ART (IFCT-0503, UK NCRI, SAKK)
Auteurs / Authors
C. Le Péchoux, N. Pourel, F. Barlési, C. Faivre-Finn, D. Lerouge, G. Zalcman, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, E. Dansin, A. Paumier, K. Peignaux, F. Thillays, J. Madeleine, E. Pichon, A. Larrouy, O. Riesterer, A. Lavolé, A. Bardet
Journal / Conference
CPLF
Année / Year
2021
PMID / session
Etude IFCT
Immunothérapie (durvalumab) néoadjuvante dans les cancers bronchiques non à petites cellules (CBNPC): résultats préliminaires de l'étude multicentrique IFCT-1601 IONESCO
Auteurs / Authors
M. Wislez , J. Mazières, A. Lavolé, G. Zalcman, O. Carré, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M. A. Massiani, A. Langlais, F. Le Pimpec-Barthes, L. Brouchet, J. Assouad, B. Milleron, D. Damotte, M. Antoine, F. Morin, V. Westeel
Journal / Conference
CPLF
Année / Year
2021
PMID / session
Etude IFCT
Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ALK+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), Etude LORLATU IFCT-1803
Auteurs / Authors
S. Baldacci, B. Besse, V. Avrillon, B. Mennecier, P. Dubray-Longeras, J. Mazières, R. Descourt, M. Duruisseaux, X. Quantin, H. Doubre, I. Monnet, D. Moro-Sibilot, S. Schneider, S. Cousin, P. Merle, J. Otto, A. Langlais, F. Morin, V. Westeel, N. Girard
Journal / Conference
CPLF
Année / Year
2021
PMID / session
Poster
Etude IFCT
Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO tria
Auteurs / Authors
F. Barlesi, M. Karimi, P. Tomasini, C. Daniel, J. Raimbourg, A-E. Quoix, A-C. Madroszyk Flandin, J. Mazieres, O. Molinier, C. Audigier-Valette, D. Moro-Sibilot, H. Morel, P-J. Souquet, I. Bieche, A. Tran-Dien, A. Jacquet, J. Adam, J-C. Soria, B. Besse
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
Autoimmune diseases in centrally reviewed Thymic Epithelial Tumors (TET)
Auteurs / Authors
J.C. Benitez Montanez, M-É. Boucher
E. Dansin, M. Kerjouan
J. Mazieres, E. Pichon, F. Thillays, P.E. Falcoz, B. Roch, Y. Oulkhouir, F. Calcagno, L. Thiberville, C. Clément-Duchêne, F. Morin, P. Missy, P.A. Thomas, J.-M. Maury, T. Molina, N. Girard, B. Besse
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced nonsmall cell lung cancer (NSCLC)
Auteurs / Authors
A. Lavole, J. Mazieres, S. Schneider, S. Brosseau, L.M. Kiakouama, L. Greillier, A. Guihot, B. Abbar, M. Baron, A. Makinson, A. Langlais, F. Morin, J-P. Spano, J. Cadranel
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
Lorlatinib for advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC): efficacy and safety data from IFCT1803 LORLATU Expanded Access Program (EAP) cohort
Auteurs / Authors
N. Girard, S. Galland Girodet
M. Duruisseaux, V. Avrillon, B. Roch, J. Otto, J. Cadranel, M. Coudurier, D. Moro-Sibilot, T. Egenod, R. Lamy, J. Bennouna, G. Zalcman, C. Ricordel, J. Tillon, L. Odier, B. Besse, P. Missy, V. Westeel, S. Baldacci
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
Post-Discontinuation Treatments in IFCTGFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma
Auteurs / Authors
G. Zalcman, S. Brosseau, J. Mazieres, J. Margery, L. Greillier,
C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre,
I. Monnet, V. Gounant, F. Rivière, R. Gervais, H. Janicot, C. Locher,
A. Langlais, J-J. Parienti, F. Morin, A. Scherpereel
Journal / Conference
WCLC
Année / Year
2019
PMID / session
Etude IFCT
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Auteurs / Authors
Herbreteau G, Langlais A, Greillier L, Audigier-Valette C, Uwer L, Hureaux J, Moro-Sibilot D, Guisier F, Carmier D, Madelaine J, Otto J, Souquet PJ, Gounant V, Merle P, Molinier O, Renault A, Rabeau A, Morin F, Denis MG, Pujol JL
Journal / Conference
Journal of Clinical Medicine
Année / Year
2020
PMID / session
Etude IFCT
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
Auteurs / Authors
Blons H, Oudart J-B, Merlio J-P, Debieuvre D, de Fraipont F, Audigier-Valette C, Escande F, Hominal S, Bringuier P‐P, Fraboulet-Moreau S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet P-J, Barlesi F, Cadranel J, Beau‐Faller M
Journal / Conference
Lung Cancer
Année / Year
2020
PMID / session
33248711
Etude IFCT
Risk factors for COVID-19 severity and mortality among solid cancer patients and its impact on anticancer treatment: a nationwide cohort study (GCO-002 CACOVID-19)
Auteurs / Authors
Lièvre A, Turpin A, Ray-Coquard I.L., Le Malicot K, Thariat J, Ahle G, Mathieu R, Sebbagh V, Debieuvre D, Canellas A,
Garcia-Larnicol M, Colle R, Hardy-Bessard A, Mansi L, Bourhis J, Gorphe P, Ursu R, Idbaih A, Zalcman G, Bouche O, Aparicio T
Journal / Conference
European Journal of Cancer
Année / Year
2020
PMID / session
Etude IFCT
Lung Cancer Screening by Low-Dose CT Scan: Baseline Results of a French Prospective Study
Auteurs / Authors
Leleu O, Basille D, Auquier M, Clarot C, Hoguet E, Pétigny V, Addi AA, Milleron B, Chauffert B, Berna P, Jounieaux V. Lung
Journal / Conference
Clinical Lung Cancer
Année / Year
2020
PMID / session
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
Auteurs / Authors
Ruppert, A-M, Beau-Faller M, Debieuvre D, Ouafik L, Westeel V, Rouquette I, Mazières J, Bringuier P-P, Monnet I, Escande F, Ricordel C, Merlio J-P, Janicot H., Lemoine A, Foucher P, Poudenx M, Morin F, Langlais A, Souquet P-J, Barlesi F, Wislez M,
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2020
PMID / session
Etude IFCT
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial
Auteurs / Authors
Quoix E, Audigier-Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Moreau L, Madelaine J, Dumont P, Margery J, Debieuvre D, Renault PA, Pujol JL, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ.
Journal / Conference
European Journal of Cancer
Année / Year
2020
PMID / session
Etude IFCT
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Auteurs / Authors
Lavole A, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano JP, Lena H, Fraisse P, Janicot H, Audigier-Valette C, Langlais A, Morin F, Makinson A, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).
Journal / Conference
European Respiratory Journal
Année / Year
2020
PMID / session
Etude IFCT
Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study
Auteurs / Authors
Kembou Nzale S, Weeks WB, Ouafik L, Rouquette I, Beau-Faller M, Lemoine A, Bringuier PP, Le Coroller Soriano AG, Barlesi F, Ventelou B
Journal / Conference
PLOS One
Année / Year
2020
PMID / session
Etude IFCT
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Auteurs / Authors
Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, Dumont P, Pouessel D, Poulet C, Fontaine-Delaruelle C, Hiret S, Dixmier A, Renault PA, Becht C, Raffy O, Dayen C, Mazieres J, Pichon E, Langlais A, Morin F, Moro-Sibilot D, Besse B
Journal / Conference
European Journal of Cancer
Année / Year
2020
PMID / session
Etude IFCT
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study
Auteurs / Authors
Fontaine-Delaruelle C, Mazières J, Cadranel J, Mastroianni B, Dubos-Arvis C, Dumont P, Monnet I, Pichon E, Locatelli-Sanchez M, Dixmier A, Coudert B, Fraboulet S, Foucher P, Dansin E, Baize N, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; IFCT10-02 BioCAST investigators
Journal / Conference
Respiratory Medicine and Research
Année / Year
2020
PMID / session
Etude IFCT
Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial
Auteurs / Authors
Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ
Journal / Conference
Clinical Cancer Research
Année / Year
2020
PMID / session
Etude IFCT
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
Auteurs / Authors
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY
Journal / Conference
Annals of Oncology
Année / Year
2020
PMID / session
The GCO-002 CACOVID-19 cohort: a French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
Auteurs / Authors
A. Lièvre,
A. Turpin,
I.L. Ray-Coquard,
K. Le Malicot,
J. Thariat,
G. Ahle,
R. Mathieu,
V. Sebbagh,
D. Debieuvre,
A. Canellas,
M-L. Garcia-Larnicol,
R. Colle,
A-C. Hardy-Bessard,
L. Mansi,
J. Bourhis,
P. Gorphe,
R. Ursu,
A. IDBAIH Ahmed,
G. Zalcman,
O. Bouche,
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
Auteurs / Authors
S. Peters, J. Pujol, U. Dafni, M. Dómine, A. Becker, J. Andrade, A. Curioni-Fontecedro, O. Molinier, D. Moro-Sibilot, K. Nackaerts, A. Insa Mollá, G. López Vivanco, J. Madelaine, S. Popat, M. Reck, H. Roschitzki-Voser, P. Mitchell, D. De Ruysscher, C. Le Pechoux, R. Stahel
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients (pts) with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFC
Auteurs / Authors
C. Le Pechoux, N. Pourel, F. Barlesi, C. Faivre-Finn, D. Lerouge, G. Zalcman, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, F. Thillays, A. Paumier, E. Dansin, K. Peignaux, J. Madelaine, E. Pichon, A. Larrouy, O. Riesterer, A. Lavole, A. Bardet
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
Auteurs / Authors
M. Wislez, J. Mazieres, A. Lavole, G. Zalcman, O. Carre, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M.A. Massiani, A. Langlais, F. Morin, F. Le Pimpec Barthes, L. Brouchet, J. Assouad, B. Milleron, D. Damotte, M. Antoine, V. Westeel
Journal / Conference
ESMO
Année / Year
2020
PMID / session
Etude IFCT
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort
Auteurs / Authors
Simon Baldacci, Virginie Avrillon, Benjamin Besse, Bertrand Mennecier, Michael Duruisseaux, Julien Mazieres, Renaud Descourt, Helene Doubre, Pascale Dubray-Longeras, Jacques Cadranel, Denis Moro-Sibilot, Charles Ricordel, Sigolène Galland-Girodet, Isabelle Monnet, Josiane Otto, Sophie Schneider, Pascale Missy, Franck Morin, Virginie Westeel, Nicolas Girard
Journal / Conference
ASCO
Année / Year
2020
PMID / session
Etude IFCT
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the Fren
Auteurs / Authors
Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J; French Cooperative Thoracic Intergroup (IFCT)
Journal / Conference
Lung Cancer
Année / Year
2019
PMID / session
Etude IFCT
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Auteurs / Authors
Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V, Bergot E, Quoix E, Lavolé A, Bigay-Game L, Pujol JL, Langlais A, Morin F, Zalcman G, Levallet G
Journal / Conference
Cancers
Année / Year
2019
PMID / session
Etude IFCT
Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study
Auteurs / Authors
Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2019
PMID / session
Etude IFCT
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Auteurs / Authors
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G
Journal / Conference
Annals of Oncology
Année / Year
2019
PMID / session
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
Auteurs / Authors
Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G
Journal / Conference
Clinical Lung Cancer
Année / Year
2019
PMID / session
Etude IFCT
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study
Auteurs / Authors
Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors
Journal / Conference
European Journal of Cancer
Année / Year
2019
PMID / session
Etude IFCT
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
Auteurs / Authors
Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G
Journal / Conference
British Journal of cancer
Année / Year
2019
PMID / session
Etude IFCT
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Auteurs / Authors
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G, on behalf of the French Cooperative Thoracic Intergroup
Journal / Conference
The Lancet Oncology
Année / Year
2019
PMID / session
Etude IFCT
A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT 1603 Trial
Auteurs / Authors
Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis MG, Bommart S, Langlais A, Morin F, Souquet PJ
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2019
PMID / session
Etude IFCT
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung)
Auteurs / Authors
Cortot A B, Madroszyk A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Raimbourg J, Hureaux J, Moreau L, Debieuvre D, Morel H, Denis M, Amour E, Morin F, Moro-Sibilot D, Cadranel J
Journal / Conference
ASCO
Année / Year
2019
PMID / session
Poster
Etude IFCT
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
Auteurs / Authors
Zalcman G, Mazieres J, Greillier L, Brosseau S, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Planchard D, Ligeza-Poisson C, Amour A, Morin F, Moro-Sibilot D, Scherpereel A.
Journal / Conference
ESMO
Année / Year
2019
PMID / session
Etude IFCT
Etude de phase II randomisée non comparative de l'anti-PD-L1 atézolizumab versus chimiothérapie comme traitement de deuxième ligne chez les patients atteints d'un cancer du poumon à petites cellules (CBPC) : résultats de l'essai IFCT-1603
Auteurs / Authors
Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J,Thiberville L, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Mazieres J, Antoine M, Langlais A, Morin F, Souquet PJ
Journal / Conference
CPLF
Année / Year
2019
PMID / session
Etude IFCT
IFCT-1702 IMPACT-SEPSIS Impact d’un événement infectieux significatif sur le pronostic des patients atteints d’un cancer bronchique non à petites cellules avancées traités par chimiothérapie de 1re ligne
Auteurs / Authors
A.C. Toffart, E. Quoix, M. Pérol, R. Stéphane, Q. Tran, P.J. Souquet, J.F. Timsit,
Journal / Conference
CPLF
Année / Year
2019
PMID / session
Etude IFCT
A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial
Auteurs / Authors
Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J,Thiberville L, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Mazieres J, Antoine M, Langlais A, Morin F, Souquet PJ
Journal / Conference
ESMO
Année / Year
2018
PMID / session
Etude IFCT
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
Auteurs / Authors
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Melaabi S, Lizard S, De Fraipont F, Longchampt E, Morin F, Zalcman G, Pignon JP, Cadranel J
Journal / Conference
Clinical Lung Cancer
Année / Year
2018
PMID / session
IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer
Auteurs / Authors
Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2018
PMID / session
Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort
Auteurs / Authors
Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2018
PMID / session
Etude IFCT
Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
Auteurs / Authors
Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT)
Journal / Conference
European Respiratory Journal
Année / Year
2018
PMID / session
Etude IFCT
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
Auteurs / Authors
Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet P.J
Journal / Conference
ESMO open
Année / Year
2018
PMID / session
Etude IFCT
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial
Auteurs / Authors
Julien Mazieres, Fabrice Barlesi, Isabelle Rouquette, Benjamin Besse, Isabelle Monnet, Clarisse Audigier-Valette, Anne Claire Toffart, Patrick-Aldo Renault, Severine Moreau Fraboulet, Sandrine Hiret, Bertrand Mennecier, Didier Debieuvre, Virginie Westeel, Philippe Masson, Anne Madroszyk, Elodie Amour, Franck Morin, Gerard Zalcman, Denis Moro-Sibilot, Pierre Jean Souquet, French Cooperative
Journal / Conference
ASCO
Année / Year
2018
PMID / session
Etude IFCT
Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced nonsmall cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial
Auteurs / Authors
Quoix E, Audigier-Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Moreau L, Madelaine J, Dumont P, Margery J, Debieuvre D, Renault PA, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ
Journal / Conference
ESMO
Année / Year
2018
PMID / session
Etude IFCT
Structuring the French Thoracic Oncology over the Last 20 Years
Auteurs / Authors
Milleron B
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2017
PMID / session
Association between lung cancer somatic mutations and occupational exposure in never-smokers
Auteurs / Authors
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; BioCAST/IFCT-1002 study investigators; to the BioCAST/IFCT- 1002 study
Journal / Conference
European Respiratory Journal
Année / Year
2017
PMID / session
Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
Auteurs / Authors
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT)
Journal / Conference
Annals of Oncology
Année / Year
2017
PMID / session
Etude IFCT
Current knowledge on perioperative treatments of non-small cell lung carcinomas
Auteurs / Authors
Brosseau S, Naltet C, Nguenang M, Gounant V, Mordant P, Milleron B, Castier Y, Zalcman G
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2017
PMID / session
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Auteurs / Authors
Tomasini P, Brosseau S, Mazières J, Merlio J.P, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F
Journal / Conference
European Respiratory Journal
Année / Year
2017
PMID / session
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
Auteurs / Authors
Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel R
Journal / Conference
ESMO open
Année / Year
2017
PMID / session
Clinical research activity of the French cancer cooperative network: Overview and perspectives
Auteurs / Authors
Dubois C, Morin F, Moro-Sibilot D, Langlais A, Seitz JF, Girault C, Salles G, Haioun C, Deschaseaux P, Casassus P, Mathiot C, Pujade-Lauraine É, Votan B, Louvet C, Delpeut C, Bardet É, Vintonenko N, Hoang Xuan K, Vo M, Michon J, Milleron B
Journal / Conference
Bulletin du cancer
Année / Year
2017
PMID / session
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK) : a French nationwide cohort retrospective study
Auteurs / Authors
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D
Journal / Conference
Oncotarget
Année / Year
2017
PMID / session
Etude IFCT
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
Auteurs / Authors
Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Journal / Conference
Annals of Oncology
Année / Year
2017
PMID / session
Etude IFCT
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
Auteurs / Authors
Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazieres J
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2017
PMID / session
Etude IFCT
Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)
Auteurs / Authors
V. Westeel, F. Barlesi, P. Foucher, J.-J. Lafitte, J. Domas, P. Girard, J. Tredaniel, M. Wislez, P. Dumont, E. Quoix, O. Raffy, D. Braun, M. Derollez, F. Goupil, J. Hermann, E. Devin, E. Pichon, J.-P. Gury, F. Morin, P.-J. Souquet
Journal / Conference
ESMO
Année / Year
2017
PMID / session
Etude IFCT
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
Auteurs / Authors
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, Thierry Urban, Catherine Ligeza-poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro-Sibilot, Gerard Zalcman
Journal / Conference
ASCO
Année / Year
2017
PMID / session
Etude IFCT
IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC
Auteurs / Authors
Maurice Perol, Clarisse Audigier-Valette, Olivier Molinier, Alexis B. Cortot, Jacques Margery, Lionel Moreau, Virginie Westeel, Pascal Dô, Fabrice Barlesi, Eric Pichon, Gerard Zalcman, Patrick Dumont, Nicolas Girard, Michel Poudenx, Julien Mazieres, Jacques Cadranel, Didier Debieuvre, Jérôme Dauba, Denis Moro-Sibilot, Pierre Jean Souquet
Journal / Conference
ASCO
Année / Year
2017
PMID / session
Etude IFCT
Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
Auteurs / Authors
Zalcman G, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Thiberville L, Urban T, Planchard D, Ligeza-Poisson C, Amour A, Morin F, Moro-Sibilot D, Scherpereel A
Journal / Conference
ESMO
Année / Year
2017
PMID / session
Etude IFCT
Prevalence of Autoimmune Diseases in Thymic Epithelial Tumors (TET) Insights from RYTHMIC
Auteurs / Authors
ME. Boucher, E. Dansin, M. Kerjouan, J. Mazieres, E. Pichon, F. Thillays, G. Massard, X. Quantin, O. Youssef, V. Westeel, L. Thiberville, C. Clement-Duchene, F. Morin, P. Thomas, N. Girard, B. Besse
Journal / Conference
WCLC
Année / Year
2017
PMID / session
Etude IFCT
Recurrences and 2Nd Primary Cancers in the IFCT-0302 Trial Assessing a CT-Scan-Based Follow-Up after Lung Cancer Surgery
Auteurs / Authors
V. Westeel, F. Barlesi, P. Foucher, J. Lafitte, J. Domas, P. Girard, J. Trédaniel, M. Wislez, B. Chahine, J. Muir, S. Dehette, J. Virally, M. Grivaux, F. Lebargy, F. Al Freijat, Nicolas Girard, E. Courau, R. Azarian, M. Farny, J. Duhamel, S. Labrune, F. Morin, P.J. Souquet
Journal / Conference
WCLC
Année / Year
2017
PMID / session
Etude IFCT
IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
Auteurs / Authors
N. Girard, O. Molinier, C. Audigier-Valette, J. Cadranel, I. Monnet, J. Hureaux, W. Hilgers, E. Fauchon, E. Fabre, Benjamin Besse, P. Brun, D. Coëtmeur, E. Quoix, P. Mourlanette, Fabrice Barlesi, S. Bordenave-Caffre, T. Egenod, P. Missy, F. Morin, D. Moro-Sibilot
Journal / Conference
WCLC
Année / Year
2017
PMID / session
Etude IFCT
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Auteurs / Authors
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A
Journal / Conference
The Lancet
Année / Year
2016
PMID / session
Etude IFCT
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Auteurs / Authors
Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.
Journal / Conference
Oncotarget
Année / Year
2016
PMID / session
Etude IFCT
Lung Cancer Screening with Chest Computed Tomography in People Living with HIV. A Review by the Multidisciplinary CANCERVIH Working Group
Auteurs / Authors
Makinson A, Le Moing V, Reynes J, Ferry T, Lavole A, Poizot-Martin I, Pujol JL, Spano JP, Milleron B
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2016
PMID / session
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01
Auteurs / Authors
Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT Team.
Journal / Conference
European Journal of Cancer
Année / Year
2016
PMID / session
Etude IFCT
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network
Auteurs / Authors
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Grellier L, Dubos C, Lindsay CR, Besse B
Journal / Conference
Lung Cancer
Année / Year
2016
PMID / session
Etude IFCT
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Auteurs / Authors
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors
Journal / Conference
The Lancet
Année / Year
2016
PMID / session
Etude IFCT
Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
Auteurs / Authors
Cadranel J, Wislez M, Langlais A, Morin F, Zalcman G
Journal / Conference
European Respiratory Journal
Année / Year
2016
PMID / session
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 0201
Auteurs / Authors
Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT team
Journal / Conference
European Journal of Cancer
Année / Year
2016
PMID / session
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE
Auteurs / Authors
Alexis B. Cortot, Clarisse Audigier-Valette, Olivier Molinier, Sylvestre Le Moulec, Fabrice Barlesi, Gerard Zalcman, Patrick Dumont, Damien Pouessel, Claire Poulet, Pierre Jean Souquet, Sandrine Hiret, Adrien Dixmier, Patrick-Aldo Renault, Alexandra Langlais, Marie Paule Lebitasy, Franck Morin, Denis Moro-Sibilot, Benjamin Besse
Journal / Conference
ASCO
Année / Year
2016
PMID / session
Etude IFCT
Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Auteurs / Authors
Leduc C, Blons H, Besse B, Merlio JP, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier PP, , Poudenx M, Rouquette I, Vaylet F, Langlais A, Missy P, Morin F, Quoix E, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M
Journal / Conference
ESMO
Année / Year
2016
PMID / session
Etude IFCT
IFCT-1001 CHIVA trial : A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous non-small cell lung cancer (NS-NSCLC)
Auteurs / Authors
Armelle Lavole, Pascale Tomasini, Isabelle Monnet, Lize Kiakouama-Maleka, Xavier Quantin, Laurent Taillade, Hervé Lena, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alain Makinson, Alexandra Langlais, Marie Paule Lebitasy, Franck Morin, Jacques Cadranel
Journal / Conference
ASCO
Année / Year
2016
PMID / session
Etude IFCT
Pathological central review of 290 thymic epithelial tumors (TET) : The national network RYTHMIC experience.
Auteurs / Authors
Thierry Molina, Maria Virginia Bluthgen, Lara Chalabreysse, Vincent Thomas De Montpreville, Anne De Muret, Veronique Hofman, Sylvie Lantuejoul, Marie Parrens, Isabelle Rouquette, Veronique Secq, Nicolas Girard, Alexander Marx, Benjamin Besse
Journal / Conference
ASCO
Année / Year
2016
PMID / session
Etude IFCT
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) : The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
Auteurs / Authors
Fabrice Barlesi, Judith Raimbourg, Pascal Do, Patrick Dumont, Jacques Cadranel, Didier Debieuvre, Werner Hilgers, Pierre Jean Souquet, Olivier Molinier, Elisabeth A. Quoix, Alexandra Langlais, Marie Paule Lebitasy, Franck Morin, Gerard Zalcman, Jaafar Bennouna
Journal / Conference
ASCO
Année / Year
2016
PMID / session
Etude IFCT
Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer
Auteurs / Authors
Milleron B, Westeel V, Gounant V, Wislez M, Quoix E
Journal / Conference
Bulletin du cancer
Année / Year
2015
PMID / session
Etude IFCT
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504
Auteurs / Authors
Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel? V,Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Journal / Conference
European Respiratory Journal
Année / Year
2015
PMID / session
Etude IFCT
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)
Auteurs / Authors
Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G
Journal / Conference
Lung Cancer
Année / Year
2015
PMID / session
Etude IFCT
Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial
Auteurs / Authors
Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT)
Journal / Conference
Annals of Oncology
Année / Year
2015
PMID / session
Etude IFCT
No impact of passive smoke on the somatic profile of lung cancers in never-smokers
Auteurs / Authors
Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, Duvert B, Cellerin L, Baize N, Taviot B, Coudurier M, Cadranel J, Missy P, Morin F, Mornex JF, Zalcman G, Souquet PJ
Journal / Conference
European Respiratory Journal
Année / Year
2015
PMID / session
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)
Auteurs / Authors
Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF
Journal / Conference
Journal of Geriatric Oncology
Année / Year
2015
PMID / session
Etude IFCT
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
Auteurs / Authors
Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G; on behalf of The French Cooperative Intergroup IFCT
Journal / Conference
European Respiratory Journal
Année / Year
2015
PMID / session
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial
Auteurs / Authors
Gerard Zalcman , Julien Mazières , Jacques Margery , Laurent Greillier , Clarisse Audigier-Valette , Denis Moro-SibilotOliver Molinier , Romain Corre , Isabelle Monnet , Valérie Gounant , Henri Janicot , Radj Gervais , Chrystele Locher , Bernard Milleron , Quan Tran , Marie Paule Lebitasy , Franck Morin , Christian Creveuil , Jean-Jacques Parienti , Arnaud Scherpereel ,
Journal / Conference
ASCO
Année / Year
2015
PMID / session
Etude IFCT
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
Auteurs / Authors
Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C
Journal / Conference
BMC Cancer
Année / Year
2014
PMID / session
Etude IFCT
RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Auteurs / Authors
Calvayrac O, Pradines A, Raymond-Letron I, Rouquette I, Bousquet E, Lauwers-Cances V, Filleron T, Cadranel J, Beau-Faller M, Casanova A, Milia J, Favre G, Mazières J
Journal / Conference
Clinical Cancer Research
Année / Year
2014
PMID / session
Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002
Auteurs / Authors
Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard, N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ; BioCAST/IFCT-1002 investigators
Journal / Conference
Clinical Cancer Research
Année / Year
2014
PMID / session
Etude IFCT
Estimating overdiagnosis in lung cancer screening
Auteurs / Authors
Couraud S, Greillier L, Milleron B; IFCT Lung Cancer Screening Group
Journal / Conference
JAMA internal Medicine
Année / Year
2014
PMID / session
Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE
Auteurs / Authors
Wislez M, Barlesi F, Besse B, Mazières J, Merle P, Cadranel J, Audigier-Valette C, Moro-Sibilot D, Gautier-Felizot L, Goupil F, Renault A, Quoix E, Souquet PJ, Madroszyck A, Corre R, Pérol D, Morin F, Zalcman G, Soria JC
Journal / Conference
Journal of Clinical Oncology
Année / Year
2014
PMID / session
Etude IFCT
Lung cancer and HIV infection
Auteurs / Authors
Lavolé A, Toper C, Belmont L, Ruppert AM, Wislez M, Cadranel J
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2014
PMID / session
Etude IFCT
Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française
Auteurs / Authors
Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; groupe de travail multidisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2014
PMID / session
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
Auteurs / Authors
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J
Journal / Conference
Annals of Oncology
Année / Year
2014
PMID / session
A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1: Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms
Auteurs / Authors
Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J
Journal / Conference
The Journal of Molecular Diagnostics
Année / Year
2014
PMID / session
National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France.
Auteurs / Authors
Benjamin Besse , Eric Pichon , Eric Dansin , Pascal Alexandre Thomas , Hervé Lena , Gerard ZalcmanJulien Mazieres , Gilbert Massard , Luc Thiberville , Virginie Westeel , Xavier Quantin , Christelle Clement-Duchene , Pierre Fournel , Hélène Senellart , Quan Tran , Thierry Jo Molina , Nicolas Girard
Journal / Conference
ASCO
Année / Year
2014
PMID / session
Second-line therapy in elderly patients with advanced non-small cell lung carcinoma: analysis of the IFCT-0501 Phase III study comparing single-agent therapy to carboplatin-based doublet therapy with fixed second-line erlotinib therapy.
Auteurs / Authors
Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; on behalf of Intergroupe Francophone de CancérologieThoracique
Journal / Conference
European Respiratory Journal
Année / Year
2014
PMID / session
Etude IFCT
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial
Auteurs / Authors
J. Trédaniel, F. Mornex
Journal / Conference
ASCO
Année / Year
2014
PMID / session
Poster discussion
Etude IFCT
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial
Auteurs / Authors
Jean-Louis Pujol , Armelle Lavole , Bertrand Mennecier , Oliver Molinier , Pierre Jean Souquet , Fabrice BarlesiHerve Le Caer , Denis Moro-Sibilot , Pierre Fournel , Jean-Philippe Oster , Patrick Chatellain , Patricia Barre , Gaelle Jeannin , Pierre Mourlanette , Marc Derollez , Dominique Herman , Patrick Renault , Charles Dayen , Franck Morin , Gerard Zalcman
Journal / Conference
ASCO
Année / Year
2014
PMID / session
Etude IFCT
Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acsé Program
Auteurs / Authors
Gilles Vassal , Natalie Hoog Labouret , Marie-Cécile Le Deley , Marta Jimenez , Frederique Nowak , Denis Moro-SibilotYann Godbert , Luc Taillandier , Jean-Yves Blay , Herve R. Bonnefoi , David Malka , Roch Houot , Thomas Aparicio , Bernard J. Escudier , Christophe Tournigand , Isabelle Ray Coquard , Pierre Laurent-Puig , Frederique Madeleine Penault-Llorca , Fabien M. Calvo , Agnes Buzyn
Journal / Conference
ASCO
Année / Year
2014
PMID / session
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
Auteurs / Authors
Westeel V, Quoix E, Puyraveau M, Lavolé A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Rivière A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarié E, Morin F, Depierre A, Milleron B; IFCT (Intergroupe Francophone de Cancérologie Thoracique)
Journal / Conference
European Journal of Cancer
Année / Year
2013
PMID / session
Etude IFCT
From the NLST randomized trial to the clinic: How should we implement individual lung cancer screening in clinical practice?
Auteurs / Authors
Couraud S, Barlesi F, Lemarié E, Zalcman G, Milleron B; pour le groupe de travail IFCT/GOLF sur le dépistage du cancer broncho-pulmonaire
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2013
PMID / session
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d’Oncologie de langue française
Auteurs / Authors
S. Couraud, A. Cortot, L. Greillier, V. Gounant, B. Mennecier, N. Girard, B. Besse, L. Brouchet, O. Castelnau, P. Frappé, G. Ferretti, L. Guittet, A. Khalil, P. Lefebure, F. Laurent, S. Liebart, O. Molinier, E. Quoix, M-P. Revel, B. Stach, P-J. Souquet, P. Thomas, J. Trédaniel, E. Lemarié, G. Zalcman, F. Barlesi, B. Milleron on behalf of the French lung cancer screening statement taskforce.
Journal / Conference
Annals of Oncology
Année / Year
2013
PMID / session
Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study
Auteurs / Authors
Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2013
PMID / session
Etude IFCT
Lung cancer in never smokers: A French national cohort (BioCAST/IFCT-1002)
Auteurs / Authors
Couraud S, Labonne S, Missy P, Morin F, Tran Q, Deroy A, Milleron B, Blanché H, Zalcman G, Souquet PJ; les membres du Groupe de travail « non-fumeurs de l’IFCT »
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2013
PMID / session
Etude IFCT
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism
Auteurs / Authors
Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A
Journal / Conference
International Journal of Cancer
Année / Year
2013
PMID / session
Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial
Auteurs / Authors
Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coëtmeur D, Monnet I, Mourlanette P, Morère JF, Soria JC, Westeel V, Morin F, Cadranel J
Journal / Conference
Journal of Clinical Oncology
Année / Year
2012
PMID / session
Etude IFCT
Randomized, Phase III Study (IFCT-GFPC 0502) of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer
Auteurs / Authors
Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B
Journal / Conference
Journal of Clinical Oncology
Année / Year
2012
PMID / session
Etude IFCT
Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study
Auteurs / Authors
Lutringer-Magnin D, Girard N, Cadranel J, Leroux C, Quoix E, Cottin V, Signore CD, Lebitasy MP, Cordier G, Vanhems P, Mornex JF
Journal / Conference
PLOS One
Année / Year
2012
PMID / session
Etude IFCT
Lung cancer in never smokers - A review
Auteurs / Authors
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ
Journal / Conference
European Journal of Cancer
Année / Year
2012
PMID / session
High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Auteurs / Authors
Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Journal / Conference
Molecular Cancer Therapeutics
Année / Year
2012
PMID / session
Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Auteurs / Authors
Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V; Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2012
PMID / session
An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Auteurs / Authors
De Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Journal / Conference
Clinical Cancer Research
Année / Year
2012
PMID / session
Etude IFCT
Cost-effectiveness of three strategies for second-line erlotinib initiation in non small-cell lung cancer: the ERMETIC Study Part 3
Auteurs / Authors
Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C; the ERMETIC Collaborative Group
Journal / Conference
European Respiratory Journal
Année / Year
2012
PMID / session
Etude IFCT
Therapeutic options in older patients with metastatic non-small cell lung cancer
Auteurs / Authors
Quoix E
Journal / Conference
Therapeutic Advances in Medical Oncology
Année / Year
2012
PMID / session
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project-Part 2)
Auteurs / Authors
Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP
Journal / Conference
Annals of Oncology
Année / Year
2012
PMID / session
Etude IFCT
Chemotherapy in elderly patients with advanced non-small cell lung cancer
Auteurs / Authors
Quoix E, Westeel V, Zalcman G, Milleron B
Journal / Conference
Lung Cancer
Année / Year
2011
PMID / session
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma
Auteurs / Authors
Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, Dufort S, de Fraipont F, Moro-Sibilot D, Cadranel J, Coll JL, Brambilla E
Journal / Conference
Journal Pathology
Année / Year
2011
PMID / session
Etude IFCT
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for th
Auteurs / Authors
Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2011
PMID / session
Etude IFCT
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Auteurs / Authors
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique
Journal / Conference
The Lancet
Année / Year
2011
PMID / session
Etude IFCT
Non-small cell lung carcinoma: Perspectives for the twenty-first century ?
Auteurs / Authors
Milleron B
Journal / Conference
Presse Médicale
Année / Year
2011
PMID / session
Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over
Auteurs / Authors
Quoix E, Ducoloné A, Mennecier B, Fraisse P
Journal / Conference
Presse Médicale
Année / Year
2011
PMID / session
Etude IFCT
A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)
Auteurs / Authors
Tredaniel J, Mornex F, Barillot I, Diaz O, Hennequin C, Le Pechoux C, Lavole A, Giraud P, Souquet PJ, Teixeira L, Vaylet F, Zalcman G, Baudrin L, Morin F, Milleron B
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2011
PMID / session
Etude IFCT
Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)
Auteurs / Authors
Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, Keus R, Hatton M, Videtic GM, Senan S, Wolfson A, Jones R, Arriagada R, Quoix E, Dunant A; on behalf of the Prophylactic Cranial Irradiation (PCI) Collaborative Group
Journal / Conference
Annals of Oncology
Année / Year
2011
PMID / session
Etude IFCT
Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Auteurs / Authors
Zalcman G, Bergot E, Lechapt E
Journal / Conference
Lung Cancer
Année / Year
2011
PMID / session
Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues
Auteurs / Authors
Bergot E, Levallet G, Creveuil C, Lechapt E, Zalcman G
Journal / Conference
Presse Médicale
Année / Year
2011
PMID / session
Update on nonsmall cell lung cancer
Auteurs / Authors
Zalcman G, Bergot E, Lechapt E
Journal / Conference
European Respiratory Review
Année / Year
2010
PMID / session
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma features
Auteurs / Authors
Duruisseaux M, Cadranel J, Pérol M, Arpin D
Journal / Conference
Current drug Targets
Année / Year
2010
PMID / session
Etude IFCT
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
Auteurs / Authors
Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot
Journal / Conference
Lung Cancer
Année / Year
2010
PMID / session
Etude IFCT
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib
Auteurs / Authors
Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J
Journal / Conference
Lung Cancer
Année / Year
2010
PMID / session
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Auteurs / Authors
Girard N, Mornex F, Douillard JY, Bossard N, Quoix E, Beckendorf V, Grunenwald, Amour E, Milleron B.
Journal / Conference
Lung Cancer
Année / Year
2010
PMID / session
Etude IFCT
Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC)
Auteurs / Authors
E. A. Quoix , J. Oster , V. Westeel , E. Pichon , G. Zalcman , L. BaudrinA. Lavole , J. Dauba , M. Lebitasy , B. J. Milleron , on behalf of IFCT
Journal / Conference
ASCO
Année / Year
2010
PMID / session
Etude IFCT
Management and outcome of French elderly patients with lung cancer: an IFCT survey
Auteurs / Authors
Quoix E, Monnet I, Scheid P, Hamadouche A, Chouaid C, Massard G, Depierre A, Souquet PJ, Braun D, Girard P, Breton JL, Lebitasy MP, Milleron B; l'Intergroupe francophone de cancérologie thoracique (IFCT)
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2010
PMID / session
Etude IFCT
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype
Auteurs / Authors
Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC, Morin F, Milleron B; IFCT-0401 Trial Group
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2009
PMID / session
Etude IFCT
Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a r
Auteurs / Authors
Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group
Journal / Conference
The Lancet Oncology
Année / Year
2009
PMID / session
Etude IFCT
Patient participation in thoracic cancer clinical trials
Auteurs / Authors
Pujol JL, Chakra M, Milleron B
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2008
PMID / session
How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study
Auteurs / Authors
Moro-Sibilot D, Barlesi F, Timsit JF, Debieuvre D, Fournel P, Gervais R, Mazieres J, Milleron B, Morin F, Perol M, Soria JC, Souquet PJ, Vergnenègre A, Zalcman G
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2008
PMID / session
Etude IFCT
IFCT-0302 trial: Randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer
Auteurs / Authors
Westeel V, Lebitasy MP, Mercier M, Girard P, Barlesi F, Blanchon F, Tredaniel J, Bonnette P, Woronoff-Lemsi MC, Breton JL, Azarian R, Falcoz PE, Friard S, Geriniere L, Laporte S, Lemarie E, Quoix E, Zalcman G, Guigay J, Morin F, Milleron B, Depierre A; Intergroupe Francophone de Cancerologie Thoracique (IFCT)
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2007
PMID / session
Etude IFCT
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01
Auteurs / Authors
Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Geneve J, Maraninchi D
Journal / Conference
Journal of Clinical Oncology
Année / Year
2007
PMID / session
Etude IFCT
The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer
Auteurs / Authors
Pieter E. Postmus, MD, PhD; Elisabeth Brambilla, MD, PhD; Kari Chansky, MS; John Crowley, PhD; Peter Goldstraw, MB, FRCS; Edward F. Patz Jr, MD; Hiroyasu Yokomise, MD; on behalf of the International Association for the Study of Lung Cancer International Staging Committee,a Cancer Research and Biostatistics,b Observers to the Committee,c and Participating Institutions
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2007
PMID / session
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
Auteurs / Authors
Ramón Rami-Porta, MD; David Ball, MD, FRANZCR; John Crowley, PhD; Dorothy J. Giroux, MS; James Jett, MD; William D. Travis, MD; Masahiro Tsuboi, MD; Eric Vallières, MD; Peter Goldstraw, MB, FRCS; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2007
PMID / session
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Auteurs / Authors
Peter Goldstraw, FRCS; John Crowley, PhD; Kari Chansky, MS; Dorothy J. Giroux, MSc; Patti A. Groome, PhD; Ramon Rami-Porta, MD; Pieter E. Postmus, PhD; Valerie Rusch, MD; Leslie Sobin, MD; on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2007
PMID / session
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
Auteurs / Authors
Ramón Rami-Porta, MD; David Ball, MD, FRANZCR; John Crowley, PhD; Dorothy J. Giroux, MS; James Jett, MD; William D. Travis, MD; Masahiro Tsuboi, MD; Eric Vallières, MD; Peter Goldstraw, MB, FRCS; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2007
PMID / session
The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Auteurs / Authors
Patti A. Groome, PhD; Vanessa Bolejack, MPH; John J. Crowley, PhD; Catherine Kennedy, RMRA; Mark Krasnik, MD; Leslie H. Sobin, MD; Peter Goldstraw, FRCS; on Behalf of the International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee and Participating Institutions
Journal / Conference
Journal of Thoracic Oncology
Année / Year
2007
PMID / session
What treatment for a patient of PS 2-3 with stage IV non-small cell lung cancer?
Auteurs / Authors
Moro-Sibilot D, Pluquet E, Zalcman G, Bréchot JM, Souquet PJ, Debieuvre D, Morin F, Morère JF
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2007
PMID / session
Standards, Options and Recommendations (SOR) for the Perioperative Treatment of Patients With Resectable and operable Non-Small Cell Lung Cancer (updated)
Auteurs / Authors
B. Besse, A. Depierre, S. Guillo, C. Séblain-El Guerche, J-Y. Douillard, A. Giniès, C. Hennequin, C. Le Péchoux, B. Milleron, P. Mouillefarine, E. Quoix, D. Moro-Sibilot, J-F. Regnard, M. Riquet, F. Vaylet, G. Zalcman ; Fédération nationale des centres de lutte contre le cancer (FNCLCC) - Intergroupe Francophone de Cancerologie Thoracique (IFCT) - Société de pneumologie de langue française (SPLF)
Journal / Conference
Oncology
Année / Year
2007
PMID / session
Follow up of non small cell lung cancer. Should patients be followed up after surgery for non-small cell lung cancer and how?
Auteurs / Authors
Westeel V
Journal / Conference
Revue des Maladies Respiratoires
Année / Year
2006
PMID / session
Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database
Auteurs / Authors
Milleron B, Westeel V, Quoix E, Moro-Sibilot D, Braun D, Lebeau B, Depierre A; French Thoracic Cooperative Group
Journal / Conference
Chest
Année / Year
2005
PMID / session
French clinical research in thoracic oncology
Auteurs / Authors
Morin F
Journal / Conference
Revue de Pneumologie Clinique
Année / Year
2004
PMID / session
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer
Auteurs / Authors
Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C; French Thoracic Cooperative Group
Journal / Conference
Journal of Clinical Oncology
Année / Year
2002
PMID / session
IFCT --French Intergroup of Thoracic Cancerology: presentation, protocols
Auteurs / Authors
Quoix E
Journal / Conference
Cancer Radiothérapie
Année / Year
2001
PMID / session